Smith & Nephew set to reap rewards of investment in sales force
This article was originally published in Clinica
Executive Summary
UK orthopaedics group Smith & Nephew expects to continue growing faster than its peers in 2005, as it feels the benefits of the recent expansion and focusing of its sales forces, and of its strong product portfolio. Chief executive Sir Christopher O'Donnell told Clinica the company was in a good position to achieve overall sales growth of 12-13% (excluding currency effects) in 2005.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.